For example, although inhibitory immune checkpoint ligand PD-L1 is a known biomarker of ICB response, it is unclear whether cancer cells escape immune cell killing by expressing PD-L1, or recruiting PD-L1+ immune cells, with studies supporting both scenarios (18). The gene discussed is CD274; the disease is cancer.